Background: Little is known about the burden of hair loss following coronavirus disease 2019 (COVID-19) infection in older adults. This study investigated the prevalence and associated factors of hair loss in older outpatients in Vietnam. Materials and methods: Between March 2022 and July 2022, this multicenter cross-sectional study included 547 older patients (aged ≥ 60 years; mean age 68.5 ± 6.9 years; men 27.1%) from three post-COVID-19 clinics. Factors associated with hair loss were assessed using logistic regression. Results: In total, 63 patients (11.5%) experienced hair loss. All of the patients with hair loss exhibited diffuse type. In the adjusted model, factors associated with hair loss were women (odds ratio [OR], 3.36; 95% confidence interval [CI], 1.43 - 7.89; P = 0.005), single or divorced in marital status (OR, 3.27; 95% CI, 1.33 - 8.02; P = 0.01), and history of COVID-19 related hospitalization (OR, 5.17; 95% CI, 2.44 - 10.95; P < 0.001). Conclusion: Our study found a substantial prevalence of post-COVID-19 hair loss in older outpatients.

The low-density lipoprotein cholesterol (LDL-C) is established as a causative agent of atherosclerotic cardiovascular disease (ASCVD) and lowering plasma LDL-C levels represents the main approach to reduce the risk of cardiovascular events. Statins remain the cornerstone of drug therapy for dyslipidemia. Although moderate- to high- intensity statin therapy has demonstrated consistent benefits for secondary prevention of cardiovascular events, statin monotherapy is insufficient to achieve the guideline-recommended LDL-C levels for high- and very high-risk patients. Some patients cannot tolerate statins, especially when taking long-term high doses. Several non-statin drugs that have a complementary mechanism of action to statins are now available, including ezetimibe, monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9 mAb), and, more recently, inclisiran, bempedoic acid, and evinacumab. Considering the recommendations from guidelines by domestic and international cardiovascular associations, combining these drugs should be contemplated to attain treatment goals for patients.